Three healthcare stocks and one technology stock that are at or near key breakout points.
Company seeks to expand the use of Rubraca to patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.
Highlighting stocks with continued technical momentum in the days and weeks after strong earnings releases.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.
| Website: | www.clovisoncology.com |
| Email: | bburkart@clovisoncology.com |
| Main Phone: | +1 303 625-5000 |
| Address: | 5500 Flatiron Parkway |
| Address 2: | Suite 100 |
| State: | CO |
| City / Town: | Boulder |
| Country: | US |
| Postal Code: | 80301 |
| Exchange: | NGS |
| CEO: | Patrick J. Mahaffy |
| Employees: | 429 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Three healthcare stocks and one technology stock that are at or near key breakout points.
Company seeks to expand the use of Rubraca to patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.
Highlighting stocks with continued technical momentum in the days and weeks after strong earnings releases.
Shares of Clovis Oncology (CLVS) are trading higher on Friday after the company reported financial results from the fourth quarter of 2013 and discussed the development of its pipeline after
It’s been a big year for biotech. Heck, it’s been a big year for most of the health care sector, but biotech’s been among the biggest gainers across the entire market, with the
Shares for Clovis Oncology (CLVS) are currently in their second straight day of over 10 percent gains. Last Friday, the company’s stock gained 15.6 percent to close at $21.81, and Monday saw
The 2013 rally in the metals markets appears to have run its course. The metal markets are now flushing the weak traders out of their positions and, at least for the gold futures and copper
As the price of gas cruises past $4 a gallon, there remain significant concerns about the capacity of the economy to continue growing if gas prices continue to rise. However, with the rising
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
